Research | Yamazoe et al. show that B-cell derived autoantibodies contribute to the development of atrial fibrillation, suggesting that targeting the humoral immune response may represent a viable therapeutic approach. https://t.co/Wn0PC1tYfA https://t.co/bU4JfhLWtI

The Khetarpal lab at UVA is seeking a research associate (postdoc)! Please see the posting and reach out with any questions!

Fresh in @NatureCVR 👇 https://t.co/zSWTn16XFz A work of ❤️‍🔥 by Masahiro & friends shows how autoantibodies lead to atrial fibrillation. This has translational potential as B cell depletion is established clinically. Need to find out which patients make those bad antibodies!

Resistin-like molecule γ attacks cardiomyocyte membranes and promotes ventricular tachycardia | Science

Please consider this unique in-person event and register! All are welcome, also our friends from industry! This will be a unique chance to discuss the latest imaging science with the Boston ❤️ community and our guests from Wash U Rob and Kory.

Discovery of a spatial niche in the bone marrow that is highly immune-privileged and may help develop new approaches to control immune tolerance (e.g. for treating or preventing autoimmune diseases) https://t.co/Rn66NslSni @Nature

Global Epidemiology of Heart Failure https://t.co/TzAEbArJ04 Published now in @NatRevCardiol

Sharing the translational followup to Maarten's AF paper last year. We introduce a drug candidate for atrial fibrillation ❤️❤️‍🔥⚡️ Awesome team effort! Therapeutic Spp1 silencing in TREM2+ cardiac macrophages suppresses atrial fibrillation

Early AF management matters. Temporal relationship of AF>HF hospitalization in this 7000+ pt analysis. Rate also increases risk #cardiotwitter #AHAJournals #Epeeps @nikhil_ahl https://t.co/mtQUDdDPsU

1/ For cardiovascular conditions, annual healthcare costs are projected to almost quadruple from $393 billion to $1490 billion between 2020 and 2050. Stroke is projected to account for the largest absolute increase in healthcare costs by 2050.

Sinus rhythm in CABANA (independent of therapy) was associated with reduced death, disabling stroke, serious bleeding, and cardiac arrest by 43% and all-cause mortality by 41% @DanMarkMD @jonpiccinisr @JEPOOLEMD @tjaredbunch #AHAJournals #Epeeps https://t.co/WIz1SRjLoz

For a joint project with Peter Libby on myocarditis, we are looking for a postdoctoral fellow with immunology background. Please email me if interested❤️‍🔥

Q: How many children did not die in the past three decades thanks to progress in global health? A: 100 million. Our World in Data

Our most complex biologic system—immunity—is reviewed in 3 new @CellCellPress papers, open-access Adaptive https://t.co/rJRBnV7u8I Innate https://t.co/PMKA6KgL7R New insights https://t.co/rJRBnV7u8I @RMedzhitov

After decades of slow progress, therapeutic vaccines that direct the immune system to attack tumours could soon become a fixture of cancer treatment

Empagliflozin after Acute Myocardial Infarction | New England Journal of Medicine

The Spatial Human #Macrophage Map is finally online in @CD_AACR! We show how phenotypically distinct macrophage populations occupy spatially segregated tissue #niches, with #IL4I1 and #SPP1 TAMs predicting opposite outcomes in colon cancer!

The world has lost a fighter whose courage will echo through generations. Horrified by the death of Sakharov Prize laureate Alexei Navalny. Russia took his freedom & his life, but not his dignity. His struggle for democracy lives on. Our thoughts are with his wife & children.

Now online! Cell surface RNAs control neutrophil recruitment

Original Article: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA trial) https://t.co/5wqdYO3aWy Editorial: What Lies beneath the Surface — Treatment of Subclinical Atrial Fibrillation https://t.co/kbXUvZsDzO #Neurology